Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

WuXi Beats Financial Estimates in Q1

publication date: May 10, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
WuXi PharmaTech, one of China’s most visible CRO/CMOs, reported first quarter revenues that were slightly better than expected, up 16% at $93.6 million. The company’s lab service revenues increased 12%, but the star performer was contract manufacturing, which climbed 35% to $19.1 million. GAAP net income was up 17% at $18.2 million, or 24 cents per share. More details....

Stock Symbol: (NYSE: WX)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors